Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q3 2024 Earnings Presentation
11 slides from Indivior Pharmaceuticals's earnings presentation, Oct 24, 2024
Slide 1: Q3 2024 Results
Q3 2024 Results October 24, 2024
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
Q3 2024 Results | October 24, 2024 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: strategic priorities, strat
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q3 2024 Highlights
Q3 2024 Results | October 24, 2024 Q3 2024 Highlights1 TOTAL NET REVENUE (NR) SUBLOCADE® NR REPORTED OP. PROFIT / ADJ. OP. PROFIT2 $307m, 13% $191m, 14% $4m / $97m, 62% Q3 2024 Key Messages: ➔ Financial results in line with October 10th update ➔ Navigating headwinds while advancing SUBLOCADE’s leade
Slide 5: Executing Against our Strategic Priorities
Q3 2024 Results | October 24, 2024 Executing Against our Strategic Priorities Grow Diversify Progress Optimize SUBLOCADE Revenue Pipeline4 Operating >$1.5bn Model • SUBLOCADE Q3 2024 NR of $191m, • SUBLOCADE ex-U.S. Q3 2024 NR • INDV-6001 (OUD5): Multiple dose • $344m of gross cash and +14% vs. Q3 2
Slide 6: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 7: Q3 2024 Financial Highlights
Q3 2024 Results | October 24, 2024 Q3 2024 Financial Highlights Key Takeaways: Operating Results: (vs. Q3 2023 unless otherwise indicated) (Reported and Adjusted1) $ mil Q3 24 Q3 23 Change ➤ Q3 2024 total NR growth of 13% Net Revenue (NR): 307 271 13% ▪ U.S. NR up 15% U.S. NR 261 227 15% ▪ ROW NR up
Slide 8: Cash & Borrowing Position
Q3 2024 Results | October 24, 2024 Cash & Borrowing Position Cash & Borrowings: Key Takeaways: Cash & investments of $344m1 ➤ YTD cash flow from operations of $94m includes ($ in mil.) $158m in settlement items which includes the Q3 2024 September 30, 2024 December 31, 2023 anti-trust settlement pay
Slide 9: FY 2024 Guidance – Updated October 10th and reiterated today
Q3 2024 Results | October 24, 2024 FY 2024 Guidance – Updated October 10th and reiterated today1 Top-Line Assumptions: ($ in mil.) ➤ Underlying U.S. BMAT2 growth of mid- to high-single digits Total Net Revenue $1,125m to $1,165m (up 5% at mid-point) ➤ OPVEE NR based on two BARDA product orders ➤ U.S
Slide 10: Appendix
Appendix
Slide 11: Financial Reconciliations
Q3 2024 Results | October 24, 2024 Financial Reconciliations Reconciliation of gross profit to adjusted gross profit Q3 Q3 YTD YTD 2024 2023 2024 2023 For the three and nine months ended September 30 $m $m $m $m Gross profit 238 225 681 665 Exceptional items and other adjustments in cost of sales 13
Indivior Pharmaceuticals — Q3 2024 Earnings Presentation on 6ix